Eli Lilly presents positive data from tirzepatide sub-studies

Substudies connected to Eli Lilly's Supass 3 phase III trial have generated favorable results for the candidate when compared to Novo Nordisk's long-acting insulin Tresiba
Photo: Mike Blake/Reuters/Ritzau Scanpix
Photo: Mike Blake/Reuters/Ritzau Scanpix

US-based pharmaceutical company Eli Lilly has presented several positive results for the drug candidate tirzepatide, which is a combination of the two hormones known respectively as GLIP-1 and GIP, at the annual meeting of the European Association for the Study of Diabetes (EASD). The company reports this in two seperate press releases on Thursday.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading